Understanding how the microbiome is involved in establishing, maintaining, and reversing obesity has been an active area of research 14,15,16 , and has included studies investigating links between the microbiome and obesity-related comorbidities such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) 17,18
A Lilly sales rep could go to the doctor and say, Look, our competitor is saying that our drug is better. Approvals to watch for Company : Novo Nordisk Molecule : CagriSema Mode of action : Targets GLP-1, amylin, and calcitonin receptors Modality : Once-weekly injection Company : Structure Therapeutics Molecule : Aleniglipron Mode of action : Targets GLP-1 receptors Modality : Once-daily pill Company : Eli Lilly and Company Molecule : Retatrutide Mode of action : Targets GLP-1, GIP, and glucagon receptors Modality : Once-weekly injections Note: GLP-1 means glucagon-like peptide 1, and GIP means gastric inhibitory polypeptide
Pigmentation melanique essentielle de la muqueuse gnitale: maladie de Laugier vulvaire (in French)
Importantly, its the supervision (medical review, monitoring, dosing, integration) that makes the difference